Results 181 to 190 of about 4,942 (259)

Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction. [PDF]

J Am Heart Assoc
Myerson M, Warden BA, Saseen JJ, Paparodis R.   +3 more
europepmc   +1 more source

A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) or ACSVD Risk-Equivalents and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Novartis
openalex   +1 more source

Comment on: Real-World Efficacy of Inclisiran in Veneto Region (Italy)—Two-thirds at Target, What About the Others? [PDF]

Luca Bonanni
openalex   +1 more source

The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease. [PDF]

Am J Prev Cardiol
Razavi AC, Shapiro MD.
europepmc   +1 more source

PCSK9 inhibitors: a promising lipid-lowering strategy for kidney transplant recipients. [PDF]

Ren Fail
Luo B, Guo L, Di W.
europepmc   +1 more source

Which is the optimal choice in lipid-lowering therapy for reducing major cardiovascular events? a network meta-analysis. [PDF]

Front Pharmacol
Niu Q, Wang Q, Chen F, Li B.
europepmc   +1 more source

Inclisiran for hypercholesterolaemia.

Australian prescriber
  +5 more sources

PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs. [PDF]

Open Heart
Ho VQT, Tran NB, Nguyen N, Arrighini GS, Downes D, Dandamudi M, Ferrara VZ, Ho THQ, Walia H, Barbagelata A, Leucker TM, Giorgi J.   +11 more
europepmc   +1 more source

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis. [PDF]

Front Pharmacol
Luo B, Sun Z, Luo H.
europepmc   +1 more source

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective. [PDF]

Front Pharmacol
Hu D, Deng X, Feng M, Zhang X, He Q, Wang T, Feng Z.   +6 more
europepmc   +1 more source